Research programme: cancer and diabetic foot ulcer therapeutics - Aurealis Pharma

Drug Profile

Research programme: cancer and diabetic foot ulcer therapeutics - Aurealis Pharma

Alternative Names: AUP 100 series; AUP 16; AUP 500 series

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Aurealis Pharma
  • Class Antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer; Diabetic foot ulcer

Highest Development Phases

  • Preclinical Diabetic foot ulcer
  • Research Cancer

Most Recent Events

  • 15 Feb 2016 Early research in Cancer in Finland (unspecified route)
  • 15 Feb 2016 Preclinical trials in Diabetic foot ulcer in Finland (unspecified route)
  • 15 Feb 2016 Aurealis Pharma plans a first-in-man trial for Diabetic foot ulcer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top